ASAlagu Subramanian

Alagu Subramanian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alagu Subramanian has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Translation readiness of model-based synthetic tabular data in healthcare: a systematic review and governance audit

    by Simone Castagno, Alagu Subramanian, Ilias E Epanomeritakis, Benjamin Gompels, Stephen McDonnell, Mark Birch, Mihaela van der Schaar, Andrew McCaskie

    Objectives: To evaluate the clinical applications and translation readiness of model-based synthetic tabular data in healthcare, and identify gaps in governance reporting that may hinder translation. Materials and Methods: We systematically searched Ovid MEDLINE and Embase (2010-August 2025; PROSPERO: CRD42025635514) for studies that generated and applied model-based synthetic tabular data in clinical contexts. Screening used a “human-in-the-loop” large language model workflow alongside independent manual review, achieving 100% sensitivity for included studies. Unlike prior reviews focused primarily on evaluation methodology, we mapped use-cases and deployment paradigms, and audited translation-readiness reporting using a predefined governance framework (validation depth, privacy, fairness, regulatory alignment). Results: Thirty-seven studies (2019-2025) were included. GANs predominated; other approaches included VAEs, diffusion models, LLM-based synthesis, and Bayesian networks. Dataset augmentation was the primary application, often improving downstream model performance for rare outcomes. Emerging applications included synthetic control cohorts and algorithmic bias mitigation. Translation-readiness reporting was limited: 34/37 studies (92%) relied solely on internal validation, 9/37 (24%) used formal privacy models, 6/37 (16%) reported explicit fairness evaluations, and 6/37 (16%) addressed regulatory alignment. Few studies distinguished “no-release” from “delayed-release” paradigms. Discussion: A systemic gap exists between methodological innovation and deployment-readiness reporting. Model-based synthetic data show clear value for augmentation and class balancing, but inconsistent reporting of validation, privacy, fairness, and regulatory considerations limits confidence in clinical deployment. Conclusion: We propose TRUST-SD (Transparency and Reporting for Utility, Safety, and Translation of Synthetic Data), an author-derived, preliminary, evidence-informed reporting checklist spanning 7 domains, as a starting point for community refinement and consensus-building.


  • Open Access

    The Paediatric ACL National Audit (PANA) study: a multicentre review of UK practice and adherence to BOAST guidelines

    by Benjamin D. Gompels, Alagu Subramanian, Ilias E. Epanomeritakis, Daniel Hide, Michael Daniel Collins, Thomas Molloy, Florence Bradshaw, Simone Castagno, Ignatius Liew, William Nabulyato, et al.


  • Open Access

    Evaluation of Subetadex-α-methyl, a Polyanionic Cyclodextrin Scaffold, as a Medical Countermeasure against Fentanyl and Related Opioids

    by Michael A. Malfatti, Heather A. Enright, Summer McCloy, Esther A. Ubick, Edward Kuhn, Alagu Subramanian, Victoria Hio Leong Lao, Doris Lam, Nicholas A. Be, Saphon Hok, et al.

    Subetadex-α-methyl (SBX-Me), a modified, polyanionic cyclodextrin scaffold, has been evaluated for its utilization as a medical countermeasure (MCM) to neutralize the effects of fentanyl and related opioids. Initial in vitro toxicity assays demonstrate that SBX-Me has a nontoxic profile, comparable to the FDA-approved cyclodextrin-based drug Sugammadex. Pharmacokinetic analysis showed rapid clearance of SBX-Me with an elimination half-life of ∼7.4 h and little accumulation in major organs. SBX-Me was also evaluated for its ability to counteract the effects of fentanyl, carfentanil, and remifentanil in rats. Recovery times in rats exposed to sublethal fentanyl doses were found to be shorter when treated with SBX-Me after opioid exposure. The recovery times were reduced from ∼35 to ∼17 min for fentanyl, ∼172 to ∼59 min for carfentanil, and ∼18 to ∼12 min for remifentanil. SBX-Me increased the elimination half-life for fentanyl and remifentanil from 5.37 to 6.42 h and 8.24 to 9.74 h, respectively. These data support SBX-Me as a solid platform from which further research can be launched for the development of a MCM against the effects of fentanyl and its analogs. Furthermore, the data suggests that SBX-Me and other analogs are attractive candidates as broad spectrum opioids targeting MCMs.


  • Open Access

    Abstract A019: eIF4A and PDCD4 expression in TNBC underlies sensitivity to natural product translation inhibitor

    by Alagu Subramanian, Haoran Xue, Kenneth G Hull, Daniel Romo, Joseph Taube

    Despite recent advances in immunotherapy and adjuvant-therapy, resistance to cancer therapeutics is common and requires novel approaches. Moreover, highly aggressive triple-negative breast cancers lack effective targeted treatments. Deregulation of translation factors is associated with the increased proliferation of TNBC cells, heightened CSC activity, and poor patient outcomes. Thus targeting translation regulatory factors upregulated in TNBC is a promising approach to developing novel treatments. Pateamine A (PatA), a natural marine macrodiolide product, inhibits RNA cap-dependent translation by binding and sequestering the eukaryotic translation initiation factor eIF4A. eIF4A promotes the translation of polypurine-rich mRNA sequences, which are enriched within breast cancer oncogenes. Here we report the anticancer efficacy of novel PatA analogs we have synthesized against breast cancer cell lines. The PatA analogs exhibited selective cytotoxicity to breast and colorectal cancers compared to non-cancerous cells measured by Cell Titer-Blue viability studies. Novel analogs show greater antiproliferative potency against models of triple-negative than against human mammary epithelial cells (HMLE). To further elucidate eIF4A as a molecular target, we conducted analyses of patient tissue samples in the Cancer Genome Atlas (TCGA). Our analyses reveal the overexpression of eIF4A in tumor tissues compared to normal tissues and gene correlation studies reveal the upregulation of key co-expressed tumor drivers including beta-catenin, fibronectin, and epithelial-to-mesenchymal transition (EMT) markers such as SNAIL and SLUG. Further analyses show a downregulation of tumor suppressor protein PDCD4, an endogenous inhibitor of eIF4A, in cancer tissues. We have generated eIF4A shRNA knockdown and PDCD4 shRNA knockdown cell lines to uncover the eIF4A-PDCD4 regulatory axis across breast adenocarcinoma and colorectal adenocarcinoma cell types. We show that the loss of eIF4A attenuates the mesenchymal and stem-like phenotype of breast cancer stem cells revealed by phenotypic assays. Our results suggest that targeting translation initiator eIF4A is an effective approach against highly proliferative and metastatic breast cancer types. The presented findings underscore the potential of eIF4A as a promising molecular target and supports translational control as a viable approach against aggressive cancers. Citation Format: Alagu Subramanian, Haoran Xue, Kenneth G Hull, Daniel Romo, Joseph Taube. eIF4A and PDCD4 expression in TNBC underlies sensitivity to natural product translation inhibitor [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A019.